We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
- Authors
Kizhakeyil, Atish; Zaini, Nurmahirah Binte Mohammed; Poh, Zhi Sheng; Wong, Brandon Han Siang; Loh, Xinpeng; Ng, Aik Seng; Low, Zun Siong; Prasannan, Praseetha; Gong, Chun; Tan, Michelle Guet Khim; Nagarajan, Chandramouli; Huang, Dachuan; Lu, Pang Wan; Lim, Jing Quan; Barrans, Sharon; Ong, Choon Kiat; Lim, Soon Thye; Chng, Wee Joo; Follows, George; Hodson, Daniel J.
- Abstract
(A) HuT78 cells were nucleofected with DDX3X siRNA or Mock siRNA (control) and then lysed after 72 h. (B) DDX3X wild-type (WT, control) and CRISPR knock-in mutant DDX3X-R475C U2392 cells were lysed. Keywords: DDX3X mutation; Hematolymphoid malignancy; Prognosis; Tumour metastasis; Drug resistance EN DDX3X mutation Hematolymphoid malignancy Prognosis Tumour metastasis Drug resistance 1 7 7 10/20/21 20211015 NES 211015 Atish Kizhakeyil, Nurmahirah Binte Mohammed Zaini and Zhi Sheng Poh contributed equally to this work. Genomic data from DDX3X-R475C mutant U2392 (A), DDX3X-depleted HuT78 (B), and DDX3X-depleted SNK1 (C) cells were analyzed by GSEA. DDX3X mutation/loss in NHL sybtype-derived cells increase cyclin-D1 expression To further investigate the role of DDX3X in NHL subtypes, we carried out whole RNA-seq analysis of mutant DDX3X-R475C U2392, DDX3X-depleted HuT78 and DDX3X-depleted SNK1 cells in comparison to their wild-type and identified 451, 1682 and 441 differentially expressed genes (DEGs), respectively (Fig.
- Subjects
DIFFUSE large B-cell lymphomas; PROGNOSIS; NON-Hodgkin's lymphoma; B cell lymphoma; CUTANEOUS T-cell lymphoma; DRUG resistance in cancer cells
- Publication
Molecular Cancer, 2021, Vol 20, Issue 1, p1
- ISSN
1476-4598
- Publication type
Article
- DOI
10.1186/s12943-021-01437-0